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Abstract
The aim of this study was to investigate the risk factors associated with CTX-M-producing Escherichia coli strains isolated from infected
or colonized patients. From 191 clinical samples, a case–control study was designed. From January 2005 to December 2007, 98 hospital-
ized patients infected or colonized with CTX-M-producing E. coli were included in the study. They were matched 1 : 1 with controls
that had a non-CTX-M-producing E. coli infection on the basis of the site of sample, the unit of hospitalization and the time at risk. The
rate of CTX-M-producing E. coli among those producing extended spectrum b-lactamases was always ‡90% from 2005 to 2008. All
strains were susceptible to carbapenems. However, we observed a high rate of co-resistance to ciproﬂoxacin (61%), sulphonamides
(86%) and gentamicin (34%). Signiﬁcant risk factors identiﬁed by multivariate analysis were recurrent infections (OR = 2.93), presence
of artiﬁcial nutrition (OR = 3.99), and recent exposure to quinolones (OR = 4.39), third- or fourth-generation cephalosporin
(OR = 3.49) and the combination of both antibiotic classes (OR = 5.50). This report highlights the dramatic increase of CTX-M-pro-
ducing E. coli and the need for changes in the use of antimicrobial drugs and in infection control measures to manage this major health
concern.
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Introduction
Extended spectrum b-lactamases (ESBLs), produced by
Gram-negative bacteria, are a major cause of bacterial multi-
drug resistance worldwide [1,2]. Until the 1990s, most ESBLs
derived from narrow-spectrum penicillinases (TEM-1/2, SHV-1)
by point mutation [3,4]. Most strains producing ESBLs were
Klebsiella pneumoniae strains and they were often associated
with nosocomial outbreaks, especially in intensive-care units.
However, a shift has occurred in the dissemination of ESBLs.
CTX-M-type enzymes (so called because they are mainly
cefotaximases) have become the most common type of
ESBLs worldwide, especially in Escherichia coli, and are
involved in both nosocomial and community-acquired infec-
tions [1,2]. They confer resistance against all b-lactam antibi-
otics apart from cephamycins and carbapenems [2].
Furthermore, CTX-M-producing E. coli strains are often
resistant to other families of antibiotics such as quinolones,
aminoglycosides or cotrimoxazole [5–8]. It remains a major
emerging health concern because the choice of effective anti-
microbial drugs is limited. However, data that focus on
CTX-M-producing E. coli incidence and risk factors are
scarce. Hence, we studied the incidence and the trend of
resistance patterns of CTX-M-producing E. coli strains iso-
lated between 2005 and 2008 at the University Hospital of
Dijon. In addition, we conducted a case–control study from
1 January 2005 to 31 December 2007. We aimed to identify
relevant clinical and molecular epidemiological risk factors
associated with colonization or infection caused by CTX-M-
producing E. coli in hospitalized patients.
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Material and Methods
Setting, subjects and design
The study was performed in the University Hospital of Dijon,
a 1600-bed teaching hospital in Burgundy, France.
To investigate the incidence and molecular epidemiology
(antimicrobial susceptibility) associated with CTX-M-produc-
ing E. coli, a subset of 191 non-duplicate—the ﬁrst for each
patient—isolates from January 2005 to December 2008 were
included in the study.
To identify risk factors, a case–control study was per-
formed. All inpatients and outpatients in whom CTX-M-pro-
ducing E. coli had been recovered from any clinical sample
between 1 January 2005 and 31 December 2007, were
included as case patients. Only strains from the ﬁrst episode
were taken into account for each case. They were matched
1 : 1 with controls that had a non-CTX-M-producing E. coli
(susceptible to cefotaxime and ceftazidime), on the basis of
the site of sample (urinary or not urinary), the unit of hospi-
talization and the time at risk. For each case, eligible controls
were given a number. Then, they were randomly selected by
a computerized method (EPI INFO 6.4d).
Deﬁnitions and variables
The time at risk was deﬁned as the time from admission to
the hospital until the date on which CTX-M-producing E. coli
was isolated for case patients. Therefore, it was zero for
outpatients.
Discrimination between nosocomial and community acqui-
sition was based on the onset of the relevant clinical syn-
drome using a 48-h cut-off following admission.
Patients were considered as colonized if they had not
shown signs or symptoms of infection potentially attributable
to CTX-M-producing E. coli.
The following data were collected retrospectively by
reviewing the medical charts: demographic data (age, sex);
underlying disease (diabetes; chronic kidney disease; neopla-
sia; pulmonary, cardiovascular or hepatic disease); isolation
site of bacteria; type of infection (nosocomial or community-
acquired infection, or colonization), type of clinical ward; the
notion of recurrent infection by E. coli, hospitalization in the
last 12 months; surgery during the previous month. Adminis-
tration of corticosteroid, immunosuppressive agent therapy
and antibiotics in the previous month before admission were
documented. Antimicrobial drugs were grouped as ‘third-
and fourth-generation cephalosporins’, ‘other b-lactams’, ‘qui-
nolones’, ‘aminoglycosides’, ‘glycopeptides’ and ‘other’, e.g.
tetracyclines, cotrimoxazole. Information on invasive devices
present during the time at risk, i.e. venous catheter, urinary
catheter, artiﬁcial nutrition (enteral and parenteral) and hae-
modialysis, was also documented.
Microbiological studies
Susceptibility to antimicrobial agents was tested by using
the disc diffusion assay on Mueller–Hinton agar (apart from
urinary samples which were tested using the Vitek 2 system
(bioMe´rieux, Lyon, France)). Strains were classiﬁed as sus-
ceptible, intermediately resistant or resistant to the anti-
biotics tested according to the recommendations of the
Antibiotic Susceptibility Testing Committee of the French
Society for Microbiology [9]. Recommendations never chan-
ged during the time period of the study. ESBL production
was screened with the double-disc synergy test [10]. Iso-
electric focusing was performed with polyacrylamide gels as
previously described [9,11]. The gene blaCTX-M was
detected by PCR using speciﬁc primers as previously
reported [11].
Statistical analysis
Antimicrobial susceptibility data were compared using the
chi-square test.
All variables were examined by univariate analysis using
the chi-square or Fisher’s exact test, as appropriate. ORs
and 95% CIs were calculated. Continuous variables were
analysed by Student’s t-test. All statistical tests were two-
tailed and p <0.05 was considered to be statistically signiﬁ-
cant. Multivariate analysis was performed by conditional
logistic regression. Variables introduced into the multivariate
analysis were those with a crude p value <0.1. Eligible vari-
ables were too numerous. Therefore, it was built as follows:
variables concerning invasive procedures were grouped and
only the signiﬁcant variable was chosen. Hence, seven vari-
ables were introduced and potential interactions between
them were considered but only four were chosen. Variables
were selected according to clinical relevance and previous
studies. We also developed a speciﬁc model that included
only recent antimicrobial treatment. STATA software, version
10.0, was used for statistical analyses.
Results
Incidence and antimicrobial susceptibility
Between 2005 and 2008, 206 ESBL-producing E. coli strains,
of which 191 were CTX-M type, were isolated. The inci-
dence of ESBL-producing E. coli among the E. coli isolates
increased from 0.9% in 2005 to 3.0% in 2008 (Table 1). The
rate of CTX-M-producing E. coli among those producing
ESBLs was always ‡90% during the past 4 years.
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All isolates were susceptible to imipenem and merope-
nem. As expected, almost all strains were resistant to
amoxicillin and ticarcillin associated with clavulanic acid. Co-
resistance was observed with gentamicin (34%), ciproﬂoxacin
(61%), cotrimoxazole (62%), tetracyclines (83%) and sulph-
onamides (86%). Between 2005 and 2008, antimicrobial sus-
ceptibilities hardly changed apart from that for piperacillin/
tazobactam (Table 2); the resistance rate decreased from
2005 to 2006 (64% vs 33%) and became stable (approxi-
mately 25%) from 2006.
Patient characteristics
During the study period, 98 patients were conﬁrmed as
having CTX-M-producing E. coli. Among these patients, the
mean age was 63.5 years, 53 (54%) were male, 65 (67%) had
received antibiotics within the previous month. Fifty-nine
patients (60%) had been hospitalized during the year before
the index admission. Most (53%) were admitted to an acute
medical ward. Forty-six per cent of patients were considered
to be infected. Cases had mainly urinary tract infections
(67%). The other characteristics of the case patients are
shown in Tables 3 and 4.
Risk factors and outcomes
Univariate analysis (Table 4) showed that various risk
factors: male sex, previous hospitalization, recurrent
infections, previous use of corticosteroids and antibiotics
(b-lactams, third- and fourth-generation cephalosporins, ﬂu-
oroquinolones and other antibiotics), and presence of
venous catheter, urinary catheter and artiﬁcial nutrition,
were associated with the occurrence of CTX-M-producing
E. coli. Underlying diseases and recent surgery were not
statistically signiﬁcant risk factors for the acquisition of
CTX-M-producing E. coli.
The multivariate logistic regression general model
(Table 5) included four variables. Recurrent infections (OR
2.93; 95% CI 1.27–6.70), recent exposure to quinolones (OR
4.39; 95% CI 1.0–17.86) and presence of artiﬁcial nutrition
(OR 3.99; 95% CI 1.04–15.24) were identiﬁed as statistically
signiﬁcant predictors of infection or colonization by CTX-M-
producing E. coli. However, recent exposure to a third- or
fourth-generation cephalosporin was of borderline signiﬁ-
cance (p 0.078). Otherwise, models with antimicrobial drugs
showed that patients who received both third- or fourth
generation cephalosporins and ﬂuoroquinolones were almost
six times (three and ﬁve times if received alone) more likely
to acquire a CTX-M-producing E. coli strain than a not CTX-
M-producing strain.
Discussion
This report highlights the dramatic increase of CTX-M-pro-
ducing E. coli strains in our hospital as observed worldwide.
We reported a high occurrence of CTX-M-producing E. coli:
up to 3% incidence in 2008. Nevertheless, most of the tested
strains were CTX-M15 (personal data) as previously
described in France [12].
Concerning antimicrobial susceptibilities, our data conﬁrm
that carbapenems remain active against CTX-M-producing
E. coli and are considered to be the treatment of choice
against serious ESBL-associated infections [2,12–16]. As for
b-lactam inhibitors—not surprisingly, tazobactam is less inac-
tivated by CTX-M type enzymes than clavulanic acid [17].
Besides, we report a low rate of resistance to piperacillin/
tazobactam. Despite geographic variations, this rate is low
compared with other studies [6,18]. Furthermore, Pitou et al.
[16] showed that Vitek 2 failed to detect piperacillin/tazobac-
tam resistance in 70 of 95 CTX-M-producing E. coli strains.
We used this system to detect resistance to piperacillin/tazo-
bactam in urinary samples so we might overestimate strain
susceptibility. Numerous studies report that ESBL-producing
E. coli have a high level of resistance to other families of anti-
biotics, particularly among CTX-M types [6,7,19]. We found
similar results, co-resistance trends were as follows: cipro-
ﬂoxacin (61%) and cotrimoxazole (62%), which is comparable
TABLE 1. Extended spectrum b-lactamases (ESBLs) and
CTX-M-producing Escherichia coli from 2005 to 2008
Total
E. coli
strains
ESBLs
(n = 208)
CTX-M
(n = 191)
Incidence
CTX-M/
ESBLs (%)
ESBLs/
Total (%)
2005 3036 27 26 96 0.9
2006 3041 34 32 94 1.1
2007 3072 51 46 90 1.7
2008 3124 94 87 93 3.0
TABLE 2. Evolution of antimicrobial susceptibilities of CTX-
M-producing Escherichia coli from 2005 to 2008
Antibiotics
Resistance (%) Variation
2005 2006 2007 2008 Mean p
AMC 100 89 100 99 97 0.016
TCC 91 96 86 77 88 0.176
TZP 64 33 17 26 35 0.002
GM 39 22 40 36 34 0.471
CIP 64 59 63 59 61 0.966
SXT 74 52 48 74 62 0.160
DO 85 75 86 84 83 0.923
SSS 85 87 86 87 86 0.996
AMC, amoxicillin/clavulanic acid; TCC, ticarcillin/clavulanic acid; TZP, piperacil-
lin/tazobactam; GM, gentamicin; CIP, ciproﬂoxacin; SXT, trimethoprim/sulpha-
methoxazole; DO, doxycyclin; SSS, sulphonamides.
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to other French data [19,20], gentamicin (34%), doxycycline
(83%) and sulphonamides (86%).
Various risk factors were analysed to determine their
association with infection or colonization by CTX-M-produc-
ing E. coli. The multivariate analysis (general model and model
with speciﬁc antimicrobial drugs) identiﬁed artiﬁcial nutrition,
recurrent infections and previous exposure to third- and
fourth-generation cephalosporins and ﬂuoroquinolones.
Recurrent infections were mostly urinary tract infection or
colonization. The case–control study conducted by Rodri-
guez-Bano et al. [21] in non-hospitalized patients also charac-
terized recurrent urinary infections as signiﬁcant risk factors.
On the other hand, we found surprisingly a strong associa-
tion between artiﬁcial nutrition (enteral or parenteral) and
acquisition of CTX-M-producing E. coli. Receipt of artiﬁcial
nutrition (especially total parenteral nutrition) has been
TABLE 3. Patients matching char-
acteristics Variable Cases (n = 98) Controls (n = 98)
Univariate
analysis p
Type of patient OR (95% CI)
Inpatients 93 93 1 (0.28–3.57) 1
Outpatients 5 5
Ward
Medicine 47 47 – –
Surgery 17 17
Intensive-care unit 20 20
Geriatric 6 6
Paediatric 3 3
Recovery 3 3
Emergency 2 2
Acquisition delay of Escherichia coli
(days, mean 95% CI)
23.6 (1.7–28) 15.1 (1–46) – 0.52
Site OR (95% CI)
Urinary 54 56 0.92 (0.52–1.62) 0.56
Non-urinary 44 42
Type of infection OR (95% CI)
Colonization/Infection 53/45 49/49 1.18 (0.67–2.72) 0.56
Nosocomial/Community-acquired
infection
22/23 22/27 1.17 (0.52–2.63) 0.69
Data are number, unless otherwise indicated.
TABLE 4. Univariate analysis of
risk factors for CTX-M-producing
Escherichia coli in hospitalized
patients
Variable Cases (n = 98) Controls (n = 98)
Univariate analysis
OR (95% CI) p
Age (mean ± SD) 64.5 ± 20.6 63.5 ± 20.9 0.99 (0.97 –1.02) 0.638
Male sex 53 38 2.07 (1.09 –3.93) 0.026
Underlying disease
Diabetes 19 25 0.7 (0.35–1.40) 0.309
Chronic kidney disease 29 23 1.54 (0.72–3.31) 0.263
Malignancy 37 31 1.46 (0.71–2.98) 0.294
Pulmonary disease 13 17 0.69 (0.29–1.63) 0.399
Cardiovascular disease 58 58 1.0 (0.54–1.83) 1.0
Hepatic disease 14 10 1.44 (0.6–3.39) 0.399
Previous hospitalizationa 59 44 1.93 (1.03–3.62 0.039
Surgeryb 21 25 0.73 (0.33–1.60) 0.437
Recurrent infectionsa 37 19 2.8 (1.35–5.79) 0.005
Recent exposure to:b
Any antibiotic 65 31 4.25 (2.30–7.74) <0.0001
b-Lactams 27 15 2.09 (1.01–4.30) 0.045
Third- and fourth-generation
cephalosporin (TFCG)
30 13 5.25 (1.79–15.38) 0.002
Quinolone 30 8 6.25 (2.17–18.03) 0.001
Aminoglycoside 16 10 1.05 (0.53–2.04) 0.886
Glycopeptide 9 8 1.2 (0.36–3.96) 0.765
TFCG + Quinolone 14 3 5.27 (1.47–19) 0.01
Previous receipt of:b
Immunosuppressive therapy 23 22 1.25 (0.33–4.68) 0.741
Corticosteroids 41 28 2.18 (1.06–4.47) 0.033
Presence of:
Mechanical ventilation 16 10 2.01 (0.80–11.16) 0.101
Venous catheter 55 44 2.83 (1.11–7.23) 0.029
Urinary catheter 34 20 3.33 (1.33–8.33) 0.010
Artiﬁcial nutrition 22 8 5.67 (1.65–19.46) 0.006
Haemodialysis 6 2 3 (0.60–14.99) 0.181
Data are number, unless otherwise indicated. NA, not applicable.
awithin 1 year, bwithin 1 month.
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identiﬁed in intensive-care units as a risk factor associated
with ESBL-producing Klebsiella pneumoniae faecal colonization
[22] and in our study, 60% of the patients who received arti-
ﬁcial nutrition were hospitalized in intensive care units,
which could explain this result.
Previous antibiotics, especially cephalosporins and quinol-
ones, are a well-characterized risk factor for infection or col-
onization with ESBL-producing E. coli [23–25]. To our
knowledge previous joint exposure to third- or fourth-gener-
ation cephalosporins in combination with ﬂuoroquinolones
had never been tested, although they are often associated in
broad-spectrum antimicrobial therapy. Moreover, in our
study the OR for combined therapy was higher than for pre-
vious exposure to third- and fourth-generation cephalospo-
rins or ﬂuoroquinolones alone. In vitro studies have shown
that ciproﬂoxacin stimulated homologous recombination and
SOS-independent recombination of divergent sequences in
E. coli [26,27]. The authors hypothesized that ﬂuoroquino-
lone treatments may modify genetic recombination in treated
bacteria, increasing the probability of acquiring new ESBLs.
Hence, these mechanisms associated with the selective pres-
sure of extensive use of broad-spectrum cephalosporins
could explain our results. Finally, we also considered antibi-
otics within 1 month of admission. Although this period has
already been reported [25,28], there is considerable hetero-
geneity in the numerous studies ranging from 90 days to
3 months,[18,19,21,24] which were less powerful than our
results.
Underlying diseases and urinary catheter use were not
found to be signiﬁcant risk factors associated with infection
or colonization by CTX-M-producing E. coli, which is con-
trary to the ﬁndings of some researchers. They were either
not statistically signiﬁcant in univariate analysis (underlying
diseases) or not selected in the general model. Indeed,
invasive procedures (mechanical ventilation, venous catheter,
urinary catheter, artiﬁcial nutrition and haemodialysis) were
ﬁrst tested in a multivariate analysis and artiﬁcial nutrition
was the only statistically signiﬁcant variable. Therefore,
urinary catheter was not selected in the general model.
Our study has limitations. Data were collected retrospec-
tively and the control group was chosen from among
patients with infection or colonization with non-CTX-M-pro-
ducing E. coli. However, this design may bias results and lead
to an overestimation of the OR, particularly with regard to
previous exposure to antibiotics [29], or to an underestima-
tion of data, as observed by Behar et al.[30]. Perhaps, to
overcome this methodological issue, a double case–control
study (whereby case patients were compared with two con-
trol groups of patients, either uninfected (or colonized)
patients or infected (or colonized) with non-CTX-M-produc-
ing E. coli) could have been designed. Nevertheless, other
parameters may seem to be taken into account. Hence the
failure to differentiate infected and colonized patients could
also alter the magnitude of some risk factors [30,31]. We
chose to include both patients colonized and those infected
with CTX-M-producing E. coli but we distinguished between
these two types to ensure that both groups were compara-
ble. We did not observe any signiﬁcant difference between
case and control groups in the proportion of infected
patients.
Finally, data focused on the risk factors associated with
CTX-M-producing E. coli are scarce.
Rodriguez-Bano et al. [32] reported only two signiﬁcant
risk factors but similar to those observed in our study: ‘prior
exposure to ﬂuoroquinolones’ and ‘oxyimino-b lactams’ in a
multivariate analysis of the subgroup ‘case patients with
CTX-M type isolates’ The case–control study conducted by
Lavigne et al. [20] identiﬁed renal disease, diabetes, urinary
tract infection, community-acquired infection, surgery and
urinary catheterization as risk factors for acquisition of
CTX-M-producing strains rather than TEM or SHV types.
We could not have chosen such a control group according
to the incidence of CTX-M types among ESBLs in our hospi-
tal. Therefore, these results were not comparable with our
data.
In conclusion, our results show the increasing incidence of
CTX-M-producing E. coli strains in Burgundy, France, and
their propensity to become multidrug-resistant pathogens.
Patients associated with putative risk factors were also iden-
tiﬁed. Our study highlights the need for changes in the use
of antimicrobial drugs, especially broad-spectrum cephalospo-
rins and ﬂuoroquinolones (especially in combination), and
the need to adopt appropriate infection control measures in
hospital and community settings.
TABLE 5. Multivariate models of risk factors for coloniza-
tion or infection caused by CTX-M-producing Escherichia
coli in hospitalized patients
Model risk factor OR (95% CI) p
General model
Recurrent infections 2.93 (1.27–6.70) 0.011
Third- and fourth-generation cephalosporin 3.11 (0.88–10.97) 0.078
Quinolone 4.39 (1.07–17.86) 0.039
Artiﬁcial nutrition 3.99 (1.04–15.24) 0.043
Model with speciﬁc antimicrobial drugs
Third- and fourth-generation cephalosporin 3.49 (1.14–10.69) 0.029
b-Lactams 1.65 (0.64–4.24) 0.298
Aminoglycoside 0.69 (0.23–2.01) 0.501
Quinolone 4.69 (1.47–14.91) 0.009
Glycopeptide 0.60 (0.11–3.03) 0.537
Third- and fourth-generation
cephalosporin + Quinolone
5.50 (1.20–25) 0.027
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